1,3-Selenazol-4-one derivatives inhibit inducible nitric oxide-mediated nitric oxide production in lipopolysaccharide-induced BV-2 cells

Biological and Pharmaceutical Bulletin

Volumn 26, Issue 12, 2003, Pages 1657-1660

  Park, Young Joon ^a   Koketsu, Mamoru ^c   Kim, Jeong Min ^b   Yeo, Joo Hong ^d   Ishihara, Hideharu ^c   Lee, Kwang Gill ^d   Kim, Sun Yeou ^b   Kim, Chong Kook ^a  

^a Seoul National University   (South Korea)

^b Kyung Hee University   (South Korea)

^c GIFU UNIVERSITY   (Japan)

^d National Institute of Animal Science   (South Korea)

Author keywords

1,3 selenazol 4 one derivative; Inducible nitric oxide synthase (iNOS); Microglia, BV 2 cell; Nitric oxide

Indexed keywords

2 (4 METHYLPHENYL) 1,3 SELENAZOL 4 ONE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; METHYL GROUP; NITRIC OXIDE; SELENAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENZYME ASSAY; ENZYME INHIBITION; MICROGLIA; MOUSE; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; AZOLES; BLOTTING, WESTERN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; ORGANOSELENIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6344241461     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.26.1657     Document Type: Article

References (20)

1. Boje K. M , Arora P K , Brain Res , 587, 250-256 (1992).
2. Banati R B., Gehrmann J., Schubert P., Kreutzberg G. W , Glia, 7, 111-118 (1993).
3. Gehrmann J., Matsumoto Y , Kreutzberg G. W., Brain Res Rev., 20, 269-287 (1995).
4. Kreutzberg G. W., Trends Neurosci., 19, 312-318 (1996).
5. Dickson D. W., Lee S. C., Mattiace L A., Yen S H., Brosnan C., Glia, 7, 75-83 (1993).
6. McGeer P. L , Kawamata T., Walker D. G , Akiyama H , Tooyama I , McGeer E G., Glia, 7, 84-92 (1993).
7. Chao C. C., Hu S , Molitor T. W , Shaskan E. G., Peterson P. K , J Immunol., 149, 2736-2741 (1992).
8. Chao C. C., Hu S , Ehrlich L., Peterson P. K , Brain Behav Immun , 9, 355-365 (1995).
9. Chou T. C., Yang S. P., Pei D., Jpn. J Pharmacol , 89, 157-163 (2002).
10. Liu B , Hong J. S , J Pharmacol Exp Ther, 304, 1-7 (2003)
11. Cho S. I , Koketsu M., Ishihara H , Matsushita M., Nairin A. C., Fukazawa H , Uehara Y., Biochim Biophys Acta, 1475, 207-215 (2000)
12. Wu W., Murakami K., Koketsu M., Yamada Y., Saiki I., Anticancer Res , 19, 5375-5382 (1999)
13. Koketsu M , Ishihara H., Wu W., Murakarni K., Saiki I., Eur. J. Pharm. Sci., 9, 157-161 (1999)
14. Deidda D., Lampis G., Maullu C , Pompei R., Isaia F , Lippolis V , Veram G , Pharmacol Res , 36, 193-197 (1997).
15. Block E , Adv. Exp Med. Biol., 401, 155-169 (1996).
16. Bronzetti G., Della C., Aretini P., Fiorio R., J. Environ. Pathol. Toxicol. Oncol., 15, 59-64 (1996).
17. Koketsu M., Takenaka Y., Ishihara H., Synthesis, 2001, 731-734 (2001).
18. Prosperi C., Scali C , Pepeu G., Casamenti F., Jpn. J. Pharmacol., 86, 230-235 (2001).
19. Vincent S. R., Prog. Neurobiol., 42, 129-160 (1994).
20. Fujita H., Tanaka J., Toku K., Tateishi N., Suzuki Y., Matsuda S., Sakanaka M., Maeda N., Glia, 18, 269-281 (1996).